Evaluation of Serum "Mac-2 Binding Protein Glycosylation Isomer (M2BPGi)" as a New Hepatic Fibrosis Marker in Patients with Chronic Hepatitis C and Changes in its Level in Response to Treatment with Direct Acting Antivirals

Main Article Content

Ramzi E, Al Shafie A, El Kassas M, Abdellatif Z, Medani H



Liver fibrosis assessment is important in patients with chronic hepatitis C infection to predict prognosis, response to treatment and for surveillance for hepatocellular carcinoma in those with liver cirrhosis. Finding reliable serum surrogate markers of liver fibrosis is unmet need. Mac-2 Binding Protein Glycosylation Isomer (M2BPGi) is a new glycoprotein biomarker that was found to correlate with liver fibrosis in east Asian population.

The aim of this study was to assess the value of M2BPGi in the diagnosis of hepatic fibrosis in chronic hepatitis C patients. Also, we aimed to evaluate the change in serum level of M2BPGi after Direct-Acting Antivirals (DDAs)- based treatment.

Patients and Methods

The study included patients with treatment-naïve chronic HCV patients who received treatment at Thabet Thabet Cairo University Hospitals. Clinic demographic data were collected.  Serum M2BPGi was measured by ELISA before treatment and 3 months after the end of treatment. ROC curves were constructed to assess the performance of M2BPGi in detecting different fibrosis stages.


The study included 120 chronic HCV patients who received DAAs . Around 29.2% of them had advanced liver fibrosis (≥F3). M2BPGi was significantly higher in patients with advanced liver fibrosis compared to those with earlier stage of fibrosis. ROC curve analysis revealed an AUROC of 0.75for M2BPGi, 0.61 for APRI and 0.56 for FIB-4 for the diagnosis of advanced fibrosis (F3-F4).


M2BPGi is a reliable marker for the diagnosis of advanced liver fibrosis in patients with chronic HCV infection.

Article Details